Potential Advantages of CUDC-101, a Multi-Targeted HDAC, EGFR, and HER2 Inhibitor, in Treating Drug Resistance and Preventing Cancer Cell Migration and Invasion

Menée sur des lignées cellulaires cancéreuses ayant acquis une résistance aux inhibiteurs d'EGFR, cette étude suggère l'efficacité d'un composé appelé CEDC-101 pour surmonter cette résistance et inhiber la migration et l'invasion des cellules tumorales

Résumé en anglais

CUDC-101 is a novel, small-molecule, anti-cancer agent targeting histone deacetylases (HDACs), epidermal growth factor receptor (EGFR), and human epidermal growth factor receptor 2 (HER2). It is currently in Phase I clinical development in patients with solid tumors. Previously, we reported that CUDC-101 has potent anti-proliferative and pro-apoptotic activity in cultured tumor cells and in vivo xenograft models. We now show that cancer cells that have acquired resistance to single-target EGFR inhibitors through upregulation of AXL or loss of E-cadherin remain sensitive to CUDC-101, which inhibits MET- and AXL-mediated signaling, restores E-cadherin expression, and reduces cell migration. CUDC-101 also efficiently inhibited the proliferation of MET-overexpressing non-small cell lung cancer and gastric cancer cell lines and inhibited the migration and invasion of invasive tumor cells. Taken together, these results suggest that coupling HDAC and HER2 inhibitory activities to an EGFR inhibitor may potentially be effective in overcoming drug resistance and preventing cancer cell migration.